Literature DB >> 1306107

A model for the formation and removal of hemoglobin adducts.

T R Fennell1, S C Sumner, V E Walker.   

Abstract

Hemoglobin adducts formed by chemical carcinogens can be used as biomarkers of exposure. The kinetics of adduct formation and removal is complex and depends on the processes involved in erythrocyte removal, adduct stability, and the duration and extent of exposure. In order to relate the formation of adducts to the extent of exposure in complex exposure scenarios, a model has been developed to describe the kinetics of accumulation and removal of adducts formed in vivo. The exposure scenario, lifetime of erythrocytes, and extent of adduct formation following a single exposure are required input parameters. Predictions of adduct accumulation have been generated for a wide variety of exposure scenarios and compared with both the solutions to equations derived for adduct formation and removal and experimental observations. Loss of adduct by removal of erythrocytes from circulation, both by senescence and random removal and as a result of chemical instability, has been simulated. Equations have been derived to describe the removal of hemoglobin adducts under conditions of exposure for less than the lifetime of the erythrocyte, when removal is initially a linear function of time. This model makes possible the comparison of data obtained from different exposure scenarios and in different species.

Mesh:

Substances:

Year:  1992        PMID: 1306107

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

1.  Dietary and lifestyle determinants of acrylamide and glycidamide hemoglobin adducts in non-smoking postmenopausal women from the EPIC cohort.

Authors:  Mireia Obón-Santacana; Leila Lujan-Barroso; Heinz Freisling; Claire Cadeau; Guy Fagherazzi; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Renée T Fortner; Heiner Boeing; J Ramón Quirós; Esther Molina-Montes; Saioa Chamosa; José María Huerta Castaño; Eva Ardanaz; Kay-Tee Khaw; Nick Wareham; Tim Key; Antonia Trichopoulou; Pagona Lagiou; Androniki Naska; Domenico Palli; Sara Grioni; Rosario Tumino; Paolo Vineis; Maria Santucci De Magistris; H B Bueno-de-Mesquita; Petra H Peeters; Maria Wennberg; Ingvar A Bergdahl; Hubert Vesper; Elio Riboli; Eric J Duell
Journal:  Eur J Nutr       Date:  2016-02-05       Impact factor: 5.614

2.  Systemic uptake, albumin and hemoglobin binding of [(14)C]2,3-butanedione administered by intratracheal instillation in male Harlan Sprague Dawley rats and oropharyngeal aspiration in male B6C3F1/N mice.

Authors:  Timothy R Fennell; Daniel L Morgan; Scott L Watson; Suraj Dhungana; Suramya Waidyanatha
Journal:  Chem Biol Interact       Date:  2015-01-02       Impact factor: 5.192

3.  Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans.

Authors:  Jiang Ma; Wei Zhang; Yisheng He; Lin Zhu; Chunyuan Zhang; Jia Liu; Yang Ye; Yuzheng Zhuge; Ge Lin
Journal:  Arch Toxicol       Date:  2020-11-18       Impact factor: 5.153

4.  Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003-2004.

Authors:  Hubert W Vesper; Samuel P Caudill; John D Osterloh; Tunde Meyers; Deanna Scott; Gary L Myers
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

5.  Measurement of hemoglobin and albumin adducts of benzo(a)pyrenediolepoxide and their rate of elimination in the female Sprague-Dawley rat.

Authors:  C Viau; M Mercier; O Blondin
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

Review 6.  Dietary acrylamide and human cancer: a systematic review of literature.

Authors:  Mandeep K Virk-Baker; Tim R Nagy; Stephen Barnes; John Groopman
Journal:  Nutr Cancer       Date:  2014-05-29       Impact factor: 2.900

7.  Benzo(a)pyrenediolepoxide-hemoglobin adducts and 3-hydroxy-benzo(a)pyrene urinary excretion profiles in rats subchronically exposed to benzo(a)pyrene.

Authors:  M Bouchard; C Viau
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort.

Authors:  Mireia Obón-Santacana; Heinz Freisling; Petra H Peeters; Leila Lujan-Barroso; Pietro Ferrari; Marie-Christine Boutron-Ruault; Sylvie Mesrine; Laura Baglietto; Renee Turzanski-Fortner; Verena A Katzke; Heiner Boeing; J Ramón Quirós; Elena Molina-Portillo; Nerea Larrañaga; María-Dolores Chirlaque; Aurelio Barricarte; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Melissa A Merritt; Marc J Gunter; Antonia Trichopoulou; Pagona Lagiou; Androniki Naska; Domenico Palli; Sabina Sieri; Rosario Tumino; Valentina Fiano; Rocco Galassom; H B As Bueno-de-Mesquita; N Charlotte Onland-Moret; Annika Idahl; Eva Lundin; Elisabete Weiderpass; Hubert Vesper; Elio Riboli; Eric J Duell
Journal:  Int J Cancer       Date:  2015-10-01       Impact factor: 7.396

Review 9.  Biomonitoring of 1,3-butadiene and related compounds.

Authors:  S Osterman-Golkar; J A Bond
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

10.  Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.

Authors:  Mireia Obón-Santacana; Leila Lujan-Barroso; Ruth C Travis; Heinz Freisling; Pietro Ferrari; Gianluca Severi; Laura Baglietto; Marie-Christine Boutron-Ruault; Renée T Fortner; Jennifer Ose; Heiner Boeing; Virginia Menéndez; Emilio Sánchez-Cantalejo; Saioa Chamosa; José María Huerta Castaño; Eva Ardanaz; Kay-Tee Khaw; Nick Wareham; Melissa A Merritt; Marc J Gunter; Antonia Trichopoulou; Eleni-Maria Papatesta; Eleni Klinaki; Calogero Saieva; Giovanna Tagliabue; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; H B Bueno-de-Mesquita; Petra H Peeters; N Charlotte Onland-Moret; Annika Idahl; Eva Lundin; Elisabete Weiderpass; Hubert W Vesper; Elio Riboli; Eric J Duell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-23       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.